Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

22.21
+0.20000.91%
Post-market: 22.660.4492+2.02%19:34 EDT
Volume:615.24K
Turnover:13.65M
Market Cap:2.51B
PE:-9.44
High:22.42
Open:22.13
Low:21.61
Close:22.01
52wk High:27.65
52wk Low:8.67
Shares:113.00M
Float Shares:108.11M
Volume Ratio:0.76
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3519
EPS(LYR):-2.4315
ROE:-50.14%
ROA:-29.72%
PB:4.26
PE(LYR):-9.13

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Argenx Se (ARGX)

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Immunome Price Target Maintained with a $31.00/share by Wedbush

Dow Jones
·
Jul 21

Immunome Begins Phase 1 Trial Dosing of Therapy for Advanced Solid Tumors

MT Newswires Live
·
Jul 20

Immunome announces first patient dosed in Phase 1 IM-3050 trial

TIPRANKS
·
Jul 20

Immunome Notifies Availability of Press Release

Reuters
·
Jul 20

Immunome - Phase 1 Trial to Evaluate Safety and Preliminary Activity of Im-3050

THOMSON REUTERS
·
Jul 20

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating Im-3050, an Fap-targeted Radioligand Therapy, in Patients with Fap-expressing Advanced Solid Tumors

THOMSON REUTERS
·
Jul 20

Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus

Simply Wall St.
·
Jul 18

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Simply Wall St.
·
Jul 17

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 11

Immunome Chief Business Officer Horn Kinney Disposes of 1,092 Common Shares Worth $27,300

Reuters
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

TIPRANKS
·
Jul 08

Immunome Flags Press Release on FDA Acceptance of Varegacestat NDA for Desmoid Tumors

Reuters
·
Jul 08

Immunome - Pdufa Target Action Date for Varegacestat Set for April 28, 2027

THOMSON REUTERS
·
Jul 08

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

THOMSON REUTERS
·
Jul 08

Immunome CMO Robert Lechleider Sells USD 1.27 Million in Common Shares

Reuters
·
Jul 08

Immunome Grants 344,000 Inducement Stock Options Priced at $21.49 Per Share

Reuters
·
Jul 08

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 08